Skip to main content
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
letter
. 2003 Jul;41(7):3450. doi: 10.1128/JCM.41.7.3450.2003

Inability to Decarboxylate Lysine as a Presumptive Marker To Identify Shiga Toxin-Producing Escherichia coli Strains of Serogroup O111

Beatriz E C Guth 1,2,*, TÂnia A T Gomes 1,2, TÂnia M I Vaz 1,2, Kinue Irino 1,2
PMCID: PMC165382  PMID: 12843119

Shiga toxin (Stx)-producing Escherichia coli (STEC) strains are important agents of gastrointestinal disease in humans, particularly since such infections may result in a life-threatening complication such as the hemolytic-uremic syndrome (HUS) (10, 12). While numerous outbreaks have been related to E. coli serotype O157:H7, several other serotypes, including O111:NM (nonmotile) and O111:H8, are well-recognized causes of bloody diarrhea and HUS in different parts of the world (1, 3, 4). In Brazil, although human STEC infections are in general restricted to sporadic cases of nonbloody diarrhea, O111:NM and O111:H8 represent the most frequent serotypes so far identified (8; T. M. I. Vaz et al., submitted for publication).

Other important O111 serotypes, including O111:H2 and O111: NM, classified as enteropathogenic E. coli (EPEC) have been a leading cause of infantile diarrhea in our country for many years (7). Moreover, serotypes O111:H9 and O111:H12 were shown to belong to other diarrheagenic E. coli categories, i.e., atypical EPEC and enteroaggregative E. coli (EAEC), respectively (2).

Therefore, identification of O111 strains only by serogrouping, as performed in most laboratories, does not characterize properly the etiologic agent. Some biochemical characteristics have been proven useful for screening O157:H7 STEC strains (5), but the lack of a distinct phenotype in non-O157 STEC strains, except the production of Stx, can be considered a drawback in the isolation and identification of this group of bacteria in most clinical routine analyses.

In a previous study conducted in our laboratory (8), we interestingly observed that O111:NM STEC strains fail to decarboxylate lysine (6). Afterwards, this observation was confirmed in a large number of O111 STEC strains (Vaz et al., submitted). Thus, these results led us to examine our laboratory collection of O111 E. coli strains belonging to the different pathogenic categories for the ability to decarboxylate lysine. We observed that none of the O111 STEC strains decarboxylate this amino acid, whereas lysine decarboxylation was positive in 435 of the 438 (99.3%) E. coli O111 strains characterized as EPEC, atypical EPEC, or EAEC or as belonging to an as-yet-undefined pathogenic group (Table 1). Moreover, the inability to decarboxylate lysine seems to be a characteristic of O111 STEC strains that distinguishes it from other important STEC serotypes (Vaz et al., submitted).

TABLE 1.

Lysine decarboxylation by E. coli O111 strains belonging to different diarrheagenic categories

Diarrheagenic category No. of strains Flagellar antigen (H)a No. (%) of strains that decarboxy- late lysine
STECb 28 H8, NM 0
EPEC 382 H2, H6, H10, NM, NT 380 (99.5)
Atypical EPEC 14 H2, H9, H33, NM, NT 13 (92.8)
EAEC 10 H12 10 (100)
Unknown 32 H4, H9, H10, H12, H15, H28, H31, H45, NM, NT 32 (100)
a

NM, nonmotile; NT, nontypeable.

b

Except for 2 strains isolated from cattle all the others were of human origin.

The ability to metabolize β-phenylpropionic acid (PPA) has been demonstrated to be of significant value in detecting EPEC strains, particularly of serogroup O111, since O111 strains belonging to different pathogenic categories were PPA negative (9, 11). Thus, according to the results described in the present study, the use of lysine decarboxylation in association with PPA will permit the identification of STEC and EPEC strains, respectively, among E. coli strains of the O111 serogroup.

In conclusion, the lysine decarboxylation assay, which is a simple, routine biochemical assay, can be an important tool and can aid in the presumptive identification of O111 STEC strains, especially in clinical laboratories that usually do not include assays to detect Stx toxins or gene sequences.

REFERENCES

  • 1.Banatvala, N., P. M. Griffin, K. D. Greene, T. J. Barret, W. F. Bibb, J. H. Green, J. G. Wells, and the Hemolytic Uremic Syndrome Study Collaborators. 2001. The United States national prospective hemolytic uremic syndrome study: microbiologic, serologic, clinical, and epidemiologic findings. J. Infect. Dis. 183:1063-1070. [DOI] [PubMed] [Google Scholar]
  • 2.Campos, L. C., T. S. Whittam, T. A. T. Gomes, J. R. C. Andrade, and L. R. Trabulsi. 1994. Escherichia coli serogroup O111 includes several clones of diarrheagenic strains with different virulence properties. Infect. Immun. 62:3282-3288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Caprioli, A., and E. Tozzi. 1998. Epidemiology of Shiga toxin-producing Escherichia coli infections in continental Europe, p. 38-48. In J. B. Kaper and A. D. O'Brien (ed.), Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. American Society for Microbiology, Washington, D.C.
  • 4.Centers for Disease Control and Prevention. 1995. Community outbreak of hemolytic uremic syndrome attributable to Escherichia coli O111:NM: South Australia, 1995. Morb. Mortal. Wkly. Rep. 44:550-551, 557-558. [PubMed] [Google Scholar]
  • 5.Chapman, P. A., C. A. Siddons, P. M., Zadik, and L. Jewes. 1991. An improved selective medium for the isolation of Escherichia coli O157. J. Med. Microbiol. 35:107-110. [DOI] [PubMed] [Google Scholar]
  • 6.Ewing, W. H. 1999. Edwards & Ewing's identification of Enterobacteriaceae, 4th ed. Elsevier Science Publishers, New York, N.Y.
  • 7.Gomes, T. A. T., P. M. Griffin, C. Ivey, L. R. Trabulsi, and S. R. T. S. Ramos. 1996. EPEC infections in São Paulo. Rev. Microbiol. 27:25-33. [Google Scholar]
  • 8.Guth, B. E. C., S. R. T. S. Ramos, A. M. F. Cerqueira, J. R. C. Andrade, and T. A. T. Gomes. 2002. Phenotypic and genotypic characteristics of Shiga toxin-producing Escherichia coli strains isolated from children in São Paulo, Brazil. Mem. Inst. Oswaldo Cruz 97:1085-1089. [DOI] [PubMed] [Google Scholar]
  • 9.Irino, K., A. M. G. Dias, E. Kano, T. M. I. Vaz, M. A. M. F. Kato, C. R. Gonçalves, M. A. M. Vieira, and T. A. T. Gomes. 2001. Metabolism of phenylpropionic acid in enteropathogenic Escherichia coli belonging to serogroup O111 and its application for diagnosis. FEMS Microbiol. Lett. 204:105-110. [DOI] [PubMed] [Google Scholar]
  • 10.Karmali, M. A. 1989. Infection by verocytotoxin-producing Escherichia coli. Clin. Microbiol. Rev. 2:15-38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Monteiro Neto, V., and L. R. Trabulsi. 1999. Phenylpropionic acid metabolism: a marker for enteropathogenic Escherichia coli clonal group 2 strains. J. Clin. Microbiol. 37:2121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Paton, J. C., and A. W. Paton. 1998. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin. Microbiol. Rev. 11:450-470. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES